Abstract: Provided herein are newly discovered methods of analyzing abaloparatide samples for abaloparatide isomers. Additionally, methods of storing and treating with abaloparatide in view of the newly discovered abaloparatide isomers are described.
Type:
Grant
Filed:
April 1, 2021
Date of Patent:
October 10, 2023
Assignee:
Radius Health, Inc.
Inventors:
Greg Williams, Naveen Palwai, David Hanley
Abstract: The present application relates to novel methods for preventing, slowing the progression of, or treating nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and/or liver fibrosis, and/or reducing the risks of liver cancer in subjects, such as HIV-infected subjects, using a GHRH molecule, e.g., trans-3-hexenoyl-GHRH(1-44)-NH2, or a pharmaceutically acceptable salt thereof. The subjects may have particular pathological features such as liver fibrosis, a hepatic fat fraction (HFF) of at least about 10%, serum alanine aminotransferase (ALT) levels of at least about 30 U/L, and/or a NAFLD Activity Score (NAS) of at least 4 or 5.
Abstract: A method for purifying Apo A-I is provided including the steps of providing a solution comprising Apo A-I and guanidine hydrochloride and filtering the solution through a filter having a pore size in a range from 15 nm to 35 nm to thereby reduce viral contamination of the Apo A-I. An Apo A-I preparation is provided having at least a 12 log LRV (log reduction value) for a parvovirus; and/or at least 9 log LRV for a non-enveloped virus; and/or at least 8.5 log LRV for a lipid enveloped virus. Also provided are pharmaceutical compositions and reconstituted high density lipoprotein formulation comprising Apo A-I and methods of treating diseases disorders or conditions.
Type:
Grant
Filed:
July 31, 2020
Date of Patent:
August 22, 2023
Assignee:
CSL Limited
Inventors:
Gary Lee Warren, Yvonne Vucica, Christoph Kempf, Martin Stucki
Abstract: The present disclosure is directed to one or more engineered peptide inhibitors against the lactate dehydrogenase A (LDHA) activity in cells. The disclosure also provides compositions, and kits including the one or more peptide inhibitors, and methods of using the one or more peptide inhibitors. The peptide inhibitors and compositions can be used for treatment of conditions in which there is abnormally high LDHA activity, such as cancer or metabolic diseases, infectious diseases, mendelian disorders, inflammatory diseases, neurodegenerative and neuropathological diseases, neuropsychological disorders, obesity and eating disorders, chronic diseases and genetic diseases.
Type:
Grant
Filed:
June 29, 2020
Date of Patent:
August 15, 2023
Assignee:
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
Inventors:
Mehdi Mollapour, Gennady Bratslavsky, Mark R. Woodford, Dimitra Bourboulia
Abstract: The present invention relates to a sensitizer-peptide conjugate for use in the treatment of cancer. In particular, the present invention relates to a sensitizer-peptide conjugate for use in the treatment of melanoma. The use of such sensitizer-peptide conjugate in photodynamic therapy or sonodynamic therapy is also disclosed. According to the present invention, there is provided a sensitizer-peptide conjugate for use in the treatment of cancer; wherein the sensitizer-peptide conjugate comprises at least one sensitizer and at least one peptide.
Type:
Grant
Filed:
June 25, 2018
Date of Patent:
August 1, 2023
Assignee:
UNIVERSITY OF ULSTER
Inventors:
John Francis Callan, Bridgeen Callan, Anthony Patrick McHale
Abstract: The present invention provides reagents for instrumentation quality control and methods of use thereof. In particular, sets of peptides or other molecules are provided for evaluating the performance of instruments with mass spectrometry (MS) and/or liquid chromatography (LC) functionalities.
Type:
Grant
Filed:
January 27, 2021
Date of Patent:
July 4, 2023
Assignee:
Promega Corporation
Inventors:
Joshua Jacques Coon, Michael M. Rosenblatt, Marjeta Urh
Abstract: SCGB-based preparations and methods to use these preparations to protect the glycocalyx in medical, veterinary, and cosmetic applications are provided. The secretoglobins (SCGBs) are a family of small secreted globular proteins present in all mammals and sharing conserved structure and thought to share similar immunomodulatory functions. Heparan sulfate proteoglycan proteins (HSPGs) are expressed on the outer membranes of cells and have carbohydrate side chains that, together, make up the glycocalyx. The glycocalyx is a protective layer surrounding all cells, acting as a filter regulating the passage of nutrients into the cell and modifying cell signaling by external factors. There are two major families of HSPGs including syndecans and glypicans, plus several other HSPGs in all mammals. SCGBs bind to, and interact with, HSPGs to further modulate cell signaling and cellular responses to external factors.
Type:
Grant
Filed:
December 2, 2019
Date of Patent:
July 4, 2023
Inventors:
Aprile L Pilon-Clayton, Melissa E. Winn
Abstract: The present disclosure provides pharmaceutical compositions comprising fibronectin based scaffold domain proteins that bind, for example, proprotein convertase subtilisin kexin-9 (PCSK9).
Abstract: The present invention relates to a polyplex for use in the treatment of castration resistant prostate cancer (CRPC) comprising a double stranded RNA (dsRNA) and a polymeric conjugate, wherein said polymeric conjugate consists of a linear polyethyleneimine (LPEl), one or more polyethylene glycol (PEG) moieties, one or more linkers and one or more targeting moieties, wherein said LPEl is covalently bound to one or more PEG moieties and each of said one or more PEG moieties is conjugated via one of the one or more linkers to one of the one or more targeting moieties, wherein each of said one or more targeting moieties is capable of binding to a cancer antigen, and wherein said cancer antigen is prostate surface membrane antigen (PSMA). Further, the invention relates to a pharmaceutical composition for use in the treatment of CRPC.
Type:
Grant
Filed:
September 27, 2018
Date of Patent:
June 20, 2023
Assignee:
TARGIMMUNE THERAPEUTICS AG
Inventors:
Esteban Pombo-Villar, Alexander Levitzki, Yael Langut, Maya Zigler, Alexei Shir, Eric Kitas
Abstract: The invention concerns novel streptavidin muteins. In one embodiment such a the mutein (a) contains at least two cysteine residues in the region of the amino acid positions 44 to 53 with reference to the amino acid sequence of wild type streptavidin as set forth at SEQ ID NO: 212 and (b) has a higher binding affinity than (i) a streptavidin mutein “1” (SEQ ID NO: 112) that comprises the amino acid sequence Val44-Thr45-Ala46-Arg47 (SEQ ID NO: 98), or (ii) wild type-streptavidin of which amino acid residues 14 to 139 are shown as SEQ ID NO: 212 for peptide ligands comprising the amino acid sequence Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 100).
Abstract: The invention features pharmaceutical compositions, methods, and kits featuring dosing gimens and oral dosage formulations for administration of echinocandin class compounds.
Abstract: The present application relates to the new the pharmaceutical combination therapy and prevention of SARS-CoV-2 and/or disease associated with this infection, including viral and bacterial pneumonia and COVID-19, using aprotinin (APR), ribavirin and/or nirmatrelvir (NIMR), the pharmaceutical kit and the pharmaceutical composition for this pharmaceutical combination therapy and prevention of SARS-CoV-2 and/or disease associated with this infection, including COVID-19.
Abstract: Provided herein are methods for treating a patient having NASH who has been determined to have a particular threshold level of serum Pro-C3 (e.g., greater than 10 ng/ML) by administering to the patient a modified Fibroblast growth factor 21 (FGF-21) in an amount and with a frequency sufficient to treat NASH. Also provided are methods for monitoring responsiveness of a patient having NASH to treatment with a modified FGF-21, the method comprising: determining the serum Pro-C3 level in a blood sample from the patient obtained during or after treatment, wherein: a decreased serum Pro-C3 level in the blood sample from the patient obtained during or after treatment, as compared to the serum Pro-C3 level in a blood sample from the patient obtained prior to treatment with the modified FGF-21, indicates that the patient is responsive to treatment with the modified FGF-21.
Type:
Grant
Filed:
September 6, 2018
Date of Patent:
May 9, 2023
Assignee:
BRISTOL-MYERS SQUIBB COMPANY
Inventors:
Edgar Davidson Charles, III, Rose C. Christian, Yi Luo
Abstract: Compounds and compositions are disclosed in which a NAMPT Drug Unit is linked to a targeting Ligand Unit through a Unit from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease, using the compounds and compositions of the invention are also disclosed.
Type:
Grant
Filed:
October 18, 2017
Date of Patent:
May 2, 2023
Assignee:
Seagen Inc.
Inventors:
Christopher Scott Neumann, Kathleen Olivas
Abstract: The present invention relates to methods for preventing or inhibiting ice recrystallisation in substances (e.g. biological materials and food products) which are susceptible to ice crystal growth upon cryopreservation and/or thawing therefrom. The methods relate to the use of compositions comprising poly(proline) or a variant or derivative thereof. Also provided are kits and compositions comprising poly(proline) which can be used in the methods of the invention.
Type:
Grant
Filed:
June 5, 2018
Date of Patent:
April 25, 2023
Assignee:
THE UNIVERSITY OF WARWICK
Inventors:
Matthew I. Gibson, Ben Graham, Trisha L. Bailey
Abstract: The disclosure relates to a method for protecting a kidney from renal injury. For example, acute renal injury may be associated with decreased or blocked blood flow in the subject's kidney or exposure to a nephrotoxic agent, such as a radiocontrast dye. The methods include administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof.
Abstract: The present invention relates to use of peptides as a therapeutic agent, wherein it has been confirmed that the peptides of the present invention significantly inhibit the activity of T cells and the differentiation of T helper 17 cells (Th17 cells), which are associated with autoimmune disease, and have remarkable effects of treating and improving arthritis in an animal model of arthritis. Therefore, the peptides may be used as an active ingredient in therapeutic agents for various autoimmune diseases such as bone disease, inflammatory disease or rheumatoid arthritis.
Type:
Grant
Filed:
September 14, 2018
Date of Patent:
April 18, 2023
Assignee:
KINE SCIENCES CO., LTD.
Inventors:
Dae Ho Cho, Kyung Eun Kim, Myun Soo Kim, Sun Young Park, Hee Young Jung
Abstract: There is disclosed a method for selectively detecting epithelial to mesenchymal transition (EMT) phenotypic cells but not noncancerous/normal epithelial cells and breast fibroblasts in a biological sample or a patient. The compositions comprise novel binding peptides that specifically bind to EMT cancer cells. EMT phenotypic cells can be identified using the specific peptides and quantitatively measured by detection of a complex of the peptide and a detectable marker. Further, nanodevices incorporating specific EMT phage ligand may be used to identify EMT cancer cells in vivo. Also disclosed are the novel binding phage peptides, and compositions and nanodevices containing the phage ligand for carrying out methods of the invention.
Abstract: The present invention provides a method in which a porous body having a monoclonal antibody to be measured immobilized in pores thereof is brought into contact with nanoparticles having a protease immobilized thereonto in a liquid to perform selective protease digestion of the monoclonal antibody and a peptide fragment obtained by the digestion is detected by liquid chromatography mass spectrometry (LC-MS), wherein the monoclonal antibody is digested with the protease in the presence of an antibody specifically binding to the monoclonal antibody or a target molecule of the monoclonal antibody.